Literature DB >> 25756243

Predictors of Disease-free Survival and Recurrence in Patients with Resected Bronchial Carcinoid Tumors.

Paul C Lee1, Nonso C Osakwe1, Navnett Narula2, Jeffrey L Port1, Subroto Paul1, Brendon M Stiles1, Weston G Andrews1, Abu Nasar1, Nasser K Altorki1.   

Abstract

BACKGROUND: Bronchial carcinoids are characterized by neuroendocrine differentiation and have distinct biological behavior, recurrence patterns, and prognosis compared with adenocarcinomas or squamous cell carcinomas. Because of their often indolent nature, it has been suggested that routine postoperative imaging surveillance may not be warranted in the majority of patients. This study aims to define the factors that predict disease-free survival (DFS) and recurrence after resection of these tumors, with the goal of identifying high-risk patients for whom image surveillance may be warranted.
METHODS: We conducted a retrospective review of a prospective database to identify patients with completely resected bronchial carcinoid tumors. Surgical procedure, histology, pathological stage, follow-up, tumor recurrence, and survival were assessed.
RESULTS: One hundred and forty-two patients were identified. Median age was 62 years and the majority was women (106). Surgical procedures included 20 wedge resections, 10 segmentectomies, 99 lobectomies, 3 bilobectomies, 2 pneumonectomies, 6 sleeve resections, and 2 bronchectomies. Pathologic stages included I (81%), II (10%), III (8%), and IV (1%). With a median follow-up of 31 months, there were seven recurrences. The 5- and 10-year overall survival rates were 92% and 75% and DFS rates were 88% and 72%, respectively. There were 34 patients with atypical carcinoids, and 6 (18%) developed recurrence, compared with 1 recurrence (1%) in the group of 108 patients with typical carcinoids (p = 0.0008). For atypical carcinoid tumors, the 5- and 10-year DFS rates were 72% and 32% versus 92% and 85% in typical carcinoid tumors (p = 0.001). Patients with more advanced tumor stage pT2-4 and pathologic N1/N2 nodal metastases had a significantly decreased 5- and 10-year DFS compared with those with early pT1 stage (p = 0.029) or those without nodal disease (p = 0.043). Multivariate Cox regression analyses showed advancing age (p = 0.001), atypical histology (p = 0.021), and advanced tumor stage (p = 0.047) were significant negative predictors for DFS.
CONCLUSION: Long-term survival after resection of bronchial carcinoids is common, especially for patients with typical carcinoid tumors. DFS can be negatively influenced by atypical histology, advanced tumor, and nodal statuses. Efforts at postoperative image surveillance should target those patients with such high-risk factors. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2015        PMID: 25756243     DOI: 10.1055/s-0035-1544211

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  5 in total

1.  Endobronchial Carcinoid Tumor Totally Occluding the Left Main Bronchus Without Producing Symptoms of Bronchial Obstruction.

Authors:  Diamantis I Tsilimigras; Demetrios Moris; Ioannis Ntanasis-Stathopoulos; Davide Patrini; Nikolaos Panagiotopoulos
Journal:  In Vivo       Date:  2017 Sep-Oct       Impact factor: 2.155

2.  A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors.

Authors:  Marta Peri; Edoardo Botteri; Eleonora Pisa; Filippo De Marinis; Antonio Ungaro; Francesca Spada; Chiara Maria Grana; Roberto Gasparri; Lorenzo Spaggiari; Nicole Romentz; Giuseppe Badalamenti; Antonio Russo; Nicola Fazio
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

3.  Metastatic Recurrence of Typical Pulmonary Carcinoid Accompanied by Carcinoid Syndrome, Successfully Treated with Octreotide LAR.

Authors:  Asako Yanagisawa; Satoshi Hirano; Shinichiro Shimizu; Takuma Hiroishi; Kohei Shikano; Noriko Hayama; Tetsuo Fujita; Hiroyuki Amano; Makoto Nakamura; Sukeyuki Nakamura; Hiroshi Tabeta
Journal:  Case Rep Oncol Med       Date:  2017-12-28

Review 4.  Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms.

Authors:  Johannes Hofland; Gregory Kaltsas; Wouter W de Herder
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

5.  Angioside: The role of Angiogenesis and Hypoxia in Lung Neuroendocrine Tumours According to Primary Tumour Location in Left or Right Parenchyma.

Authors:  Anna La Salvia; Raffaella Carletti; Monica Verrico; Tiziana Feola; Giulia Puliani; Massimiliano Bassi; Franz Sesti; Angelina Pernazza; Rossella Mazzilli; Giuseppe Lamberti; Alessandra Siciliani; Massimiliano Mancini; Chiara Manai; Federico Venuta; Mohsen Ibrahim; Silverio Tomao; Giulia D'Amati; Cira Di Gioia; Elisa Giannetta; Federico Cappuzzo; Antongiulio Faggiano
Journal:  J Clin Med       Date:  2022-10-09       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.